期刊文献+

Sphingosine-1-phosphate signaling and the gut-liver axis in liver diseases 被引量:3

原文传递
导出
摘要 The liver is the central organ involved in lipid metabolism and the gastrointestinal(GI)tract is responsible for nutrient absorption and partitioning.Obesity,dyslipidemia and metabolic disorders are of increasing public health concern worldwide,and novel therapeutics that target both the liver and the GI tract(gut-liver axis)are much needed.In addition to aiding fat digestion,bile acids act as important signaling molecules that regulate lipid,glucose and energy metabolism via activating nuclear receptor,G protein-coupled receptors(GPCRs),Takeda G protein receptor 5(TGR5)and sphingosine-1-phosphate receptor 2(S1PR2).Sphingosine-1-phosphate(S1P)is synthesized by two sphingosine kinase isoforms and is a potent signaling molecule that plays a critical role in various diseases such as fatty liver,in-flammatory bowel disease(IBD)and colorectal cancer.In this review,we will focus on recent findings related to the role of S1P-mediated signaling pathways in the gut-liver axis.
出处 《Liver Research》 2019年第1期19-24,共6页 肝脏研究(英文)
基金 This work was supported by the USA National Institutes of Health(NIH)grants R01 DK104893 and R01DK-057543 VA Merit Award I01BX004033 and 1I01BX001390 Research Career Scientist Award(IK6BX004477)from the Department of Veterans Affairs.
  • 相关文献

参考文献4

二级参考文献12

  • 1Yan-Yan Ma,Lin Li,Chao-Hui Yu,Zhe Shen,Li-Hua Chen,You-Ming Li.Effects of probiotics on nonalcoholic fatty liver disease:A meta-analysis[J].World Journal of Gastroenterology,2013,19(40):6911-6918. 被引量:29
  • 2Maitreyi Raman,Iftikhar Ahmed,Patrick M. Gillevet,Chris S. Probert,Norman M. Ratcliffe,Steve Smith,Rosemary Greenwood,Masoumeh Sikaroodi,Victor Lam,Pam Crotty,Jennifer Bailey,Robert P. Myers,Kevin P. Rioux.Fecal Microbiome and Volatile Organic Compound Metabolome in Obese Humans With Nonalcoholic Fatty Liver Disease[J].Clinical Gastroenterology and Hepatology.2013(7)
  • 3Z. M. Younossi,M. J. Reyes,A. Mishra,R. Mehta,L. Henry.Systematic review with meta‐analysis: non‐alcoholic steatohepatitis ‐ a case for personalised treatment based on pathogenic targets[J].Aliment Pharmacol Ther.2014(1)
  • 4J. P. Ong,Z. M. Younossi.Editorial: probiotics in NASH – more studies are needed[J].Aliment Pharmacol Ther.2014(2)
  • 5A. Alisi,G. Bedogni,G. Baviera,V. Giorgio,E. Porro,C. Paris,P. Giammaria,L. Reali,F. Anania,V. Nobili.Randomised clinical trial: the beneficial effects of VSL #3 in obese children with non‐alcoholic steatohepatitis[J].Aliment Pharmacol Ther.2014(11)
  • 6Vivek Kesar,Joseph A. Odin.Toll‐like receptors and liver disease[J].Liver Int.2014(2)
  • 7Valentina Giorgio,Luca Miele,Luigi Principessa,Francesca Ferretti,Maria Pia Villa,Valentina Negro,Antonio Grieco,Anna Alisi,Valerio Nobili.Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity[J].Digestive and Liver Disease.2014
  • 8Teresa Requena,Paul Cotter,Danit R. Shahar,Charlotte R. Kleiveland,M. Carmen Martínez-Cuesta,Carmen Peláez,Tor Lea.Interactions between gut microbiota, food and the obese host[J].Trends in Food Science & Technology.2013(1)
  • 9Luca Miele,Giuseppe Marrone,Cristiano Lauritano,Consuelo Cefalo,Antonio Gasbarrini,Chris Day,Antonio Grieco.Gut-liver Axis and Microbiota in NAFLD: Insight Pathophysiology for Novel Therapeutic Target[J].Current Pharmaceutical Design.2013(29)
  • 10Ding-You Li,Min Yang,Sarah Edwards,Shui-Qing Ye.Nonalcoholic Fatty Liver Disease[J].Journal of Parenteral and Enteral Nutrition.2013(6)

共引文献147

同被引文献24

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部